Post Prandial Blood GlucoseNCT07541794
Relaxing Virtual Reality Use and Blood Glucose Response to Food (ReViR) Study
A study testing A relaxing VR environment, A stress-inducing VR game and A VR clinical room in people with Post Prandial Blood Glucose and Feasibility Pilot Study, run by University of Manitoba at 1 site in Canada.
Trial summary
This randomized cross-over pilot clinical trial aims to evaluate the feasibility and effect of a relaxing virtual reality (VR) experience on glucose response after white bread consumption, compared to a stress-inducing VR, a VR clinical room, and a real clinical room, in healthy adults. Read more about this study
- Who is it for?
- Ages 18 to 50 yearsHealthy volunteers can take part
- Conditions the study is for
- Post Prandial Blood Glucose, Feasibility Pilot Study
- What is being tested?
- A relaxing VR environment, A stress-inducing VR game and A VR clinical room
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 20 participants
- Where
- 1 siteCanada
- Study dates
- 4 Sep 2026to 1 Mar 2027
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 50 years
- All sexes
- Healthy volunteers accepted
- Adult
Participants must meet all of the following criteria to be eligible for the study:
- Aged between 18 and 50 years, of any sex.
- Body mass index (BMI) between 18.9 and 29.9 kg/m².
- Fasting blood glucose between 3.5 and 5.6 mmol/L.
- They typically consume breakfast as part of their regular routine.
- Willing and able to provide written informed consent.
- In the opinion of the Investigator, the participant is capable of understanding and adhering to all study requirements.
Participants will be excluded if they meet any of the following conditions:
- Fasting blood glucose ≥ 5.6 mmol/L or < 3.5 mmol/L.
- Medical conditions that contraindicate the use of virtual reality (VR) headsets, including panic disorders, seizure disorders, migraines, certain vision impairments, or VR-related motion sickness.
- A history of allergy or adverse reaction to white bread.
- Current adherence to a special diet or use of supplements/medications that may affect carbohydrate metabolism, heart rate, or the nervous system within the last 6 months.
- Medical history of hypertension, HIV/AIDS, hepatitis, type 1 or type 2 diabetes, cardiovascular or pulmonary diseases, or gastrointestinal disorders impacting carbohydrate metabolism.
- Major physical injury or surgical procedure within the last 3 months.
- Participation in any other randomized controlled trial within the previous 3 months.
- Currently pregnant, breastfeeding, or planning to become pregnant during the study period.
- Being unable to consume the test meal within the required 10-minute timeframe.
- History of cancer within the past two years, excluding non-melanoma skin cancers.
- Current or recent (within 12 months) excessive alcohol use defined as more than 14 standard drinks per week (1 drink = 12 oz beer, 5 oz wine, or 1.5 oz spirits).
- Significant weight change (gain or loss exceeding 3.5 kg) in the past 3 months.
- Inability to provide written informed consent.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Canada1 site, 1 recruiting
- Recruiting
University of Manitoba
Winnipeg, Manitoba, R3T 2N2
Dylan MacKay, 2047828124, dylan.mackay@umanitoba.ca
Dylan MacKay, PhD
About this study
This randomized cross-over pilot clinical trial aims to evaluate the feasibility and effect of a relaxing virtual reality (VR) experience on glucose response after white bread consumption, compared to a stress-inducing VR, a VR clinical room, and a real clinical room, in healthy adults. Participants will use a head-mounted display to experience either one of the VR environments, or they will simply sit in an actual clinical room for 15 minutes. After this pre-meal condition, participants will consume 66 grams of white bread within 10 minutes, accompanied by 250 mL of water. They will then continue their assigned pre-meal condition for one hour, followed by an additional hour of sitting in the lab for further assessments.
The feasibility of the study will be assessed by calculating: 1) Screening to randomization ratio, 2) Recruitment rate of participants per week, 3) Retention rate, 4) Data Completeness of Finger-Prick Glucose Measurements, and 5) VR intervention tolerability measured by Simulator Sickness Questionnaire (SSQ) score. Postprandial glucose response, stress levels, heart rate, and skin conductance will be assessed at baseline (15 minutes before white bread consumption), immediately before consumption (time 0), and at 15, 30, 45, 60, 90, and 120 minutes post-consumption. Palatability will be evaluated immediately after the meal consumption. Motivation to eat will also be assessed at 0, 15, 30, 45, 60, 90, and 120 minutes. Sense of presence will be measured immediately after VR exposure. Additionally, simulator sickness will be assessed at the beginning of the study and after VR exposure.
The results will help us better understand the potential feasibility and benefits of using relaxing VR for postprandial glucose management. These findings will also provide evidence to optimize the design of future definitive randomized clinical trials and enhance the development of VR interventions.
- Being tested
- A relaxing VR environment, A stress-inducing VR game, A VR clinical room, A non-VR clinical room
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
A relaxing VR environmentDevice
The TRIPP application, a relaxing VR environment that provides an immersive mindfulness.
A stress-inducing VR gameDevice
"Affected: The Manor Complete Edition," which is a horror-themed VR game involving a walk-through of a haunted house designed to evoke stress (Positive control).
A VR clinical roomDevice
A VR clinical room resembling the real clinical room as a sham control
A non-VR clinical roomOther
A non-VR clinical room (real clinical environment).
| Study group | Role | What they receive |
|---|---|---|
| A relaxing VR environment | Experimental | Not described Receives: Device: A relaxing VR environment |
| A stress-inducing VR game | Active comparator | Not described Receives: Device: A stress-inducing VR game |
| A VR clinical room | Sham comparator | Not described Receives: Device: A VR clinical room |
| A non-VR clinical room | Other | Not described Receives: Other: A non-VR clinical room |
What is being measured
The primary outcome is the main question the study is designed to answer.
The feasibility of VR interventions for blood glucose response to food
The feasibility of VR interventions for blood glucose response to food will be evaluated using a predefined red-yellow-green progression framework. This framework assesses five key feasibility metrics related to the study: screening to randomization ratio, recruitment rate, retention, data completeness of finger-prick glucose measurements, and VR intervention tolerability. Each metric will be judged against the three zones: green indicates feasibility, yellow suggests that modifications are needed, and red signifies that the trial is not feasible for a larger study in its current design.
Measured: Feasibility will be measured through study completion, an average of 4 weeks.
Secondary outcomes (8)
Postprandial glucose response
We will use a calibrated finger-prick device to measure blood glucose concentration.
Measured: Capillary blood glucose will be measured at baseline and periprocedural.
Stress levels
Stress level will be assessed using the Visual Analog Scale (VAS), a 10-cm line on which 0 indicates the lowest level of stress and 10 indicates the highest.
Measured: Visual analog scale (VAS) measuring self-reported stress levels will be completed at the baseline and periprocedural.
Skin conductance
MINDFILD@ eSence Skin Response Units will be used to evaluate skin conductance
Measured: Skin conductance will be measured at baseline and periprocedural.
Heart rate
MINDFILD@ eSense PULSE-Heart Rate Variability sensors will be used for heart rate.
Measured: Heart rate will be measured at baseline and periprocedural.
Participants' sense of presence in VR
Participants' sense of presence in VR will be evaluated using the iGroup Presence Questionnaire, a 14-item instrument with a 7-point scale ranging from -3 to +3, where -3 indicates strong disagreement and +3 indicates strong agreement with the statement
Measured: It will be measured immediately after exposure to VR environments
Simulator sickness
Simulator sickness will be assessed using the Simulator Sickness Questionnaire (SSQ), which includes sixteen items representing the severity of symptoms that may occur due to exposure to a VR environment, rated from none to severe.
Measured: It will be measured at the beginning and immediately after VR exposure.
Palatability
To measure palatability, a 3-item, self-reported questionnaire will be used. Each item can be answered with a Visual Analog Scale (VAS), a 10 cm line indicating the extent of the participant's feeling, while 0 represents the lowest possible rating and 10 represents the highest.
Measured: The Visual Analog Scale (VAS) measuring self-reported palatability will be completed right after the consumption of the white bread meal.
Appetite
Appetite will be assessed using the Visual Analog Scale (VAS), a five-item questionnaire in which each item is represented by a 10 cm line indicating the extent of the participant's feeling. On each line, 0 represents the lowest possible rating and 10 represents the highest.
Measured: The visual analog scale (VAS) measuring self-reported appetite will be completed periprocedurally
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Apr 2026
- Study start4 Sep 2026
- Primary completion27 Feb 2027 (estimated)
- Study completion1 Mar 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Post Prandial Blood GlucoseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Manitoba
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Dylan MacKay, University of Manitoba
- Investigators
- Dylan MacKay, PhD, Principal investigator, University of Manitoba
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07541794
- Sponsor's protocol ID
- IRB00012696
- Status last verified
- Sep 2026
- First submitted
- 18 Aug 2025
- Last updated
- 21 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No